Literature DB >> 12423311

Reactivation of latent tuberculosis by an inhibitor of inducible nitric oxide synthase in an aerosol murine model.

Tania Botha1, Bernhard Ryffel.   

Abstract

Exposure to Mycobacterium tuberculosis results in clinical tuberculosis only in a small percentage of healthy individuals. In most instances the bacilli are controlled by the immune system and survive in a latent state within granuloma. Immunosuppression, however, may result in reactivation of infection, resulting in clinical disease. Using a low-dose aerosol infection (30 colony-forming units) in mice, we describe a short-duration model for studying spontaneous and drug-induced reactivation of anti-tuberculous drug-treated, latent tuberculosis infection. Although a 4-week treatment with rifampicin and isoniazid reduced the number of bacilli to undetectable levels, the infection spontaneously reactivated following therapy. By contrast, an 8-week treatment period induced a state of latent infection, requiring immunosuppression to reactivate infection. Finally, a 12-week treatment period eliminated the bacilli completely and aminoguanidine did not induce reactivation of infection. In view of the fact that therapy in the selected protocol reduces the mycobacterial load to undetectable levels, the data suggest that an 8-week treatment period is necessary and sufficient to mount protective immunity in mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12423311      PMCID: PMC1782808          DOI: 10.1046/j.1365-2567.2002.01511.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  17 in total

1.  The global tuberculosis situation and the new control strategy of the World Health Organization.

Authors:  A Kochi
Journal:  Tubercle       Date:  1991-03

2.  Reactivation of latent tuberculosis: variations on the Cornell murine model.

Authors:  C A Scanga; V P Mohan; H Joseph; K Yu; J Chan; J L Flynn
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

Review 3.  Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: recrudescence of residuals of the primary infection or exogenous reinfection?

Authors:  W W Stead
Journal:  Am Rev Respir Dis       Date:  1967-05

4.  A mouse model of the recrudescence of latent tuberculosis in the elderly.

Authors:  I M Orme
Journal:  Am Rev Respir Dis       Date:  1988-03

5.  The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy.

Authors:  J Grosset
Journal:  Bull Int Union Tuberc       Date:  1978-03

Review 6.  Tuberculosis. Scientific blueprint for tuberculosis drug development.

Authors: 
Journal:  Tuberculosis (Edinb)       Date:  2001       Impact factor: 3.131

7.  Tuberculosis: a global overview of the situation today.

Authors:  P Sudre; G ten Dam; A Kochi
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

8.  Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic.

Authors:  M C Raviglione; D E Snider; A Kochi
Journal:  JAMA       Date:  1995-01-18       Impact factor: 56.272

Review 9.  HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention.

Authors:  J P Narain; M C Raviglione; A Kochi
Journal:  Tuber Lung Dis       Date:  1992-12

10.  Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli.

Authors:  R M McCune; F M Feldmann; W McDermott
Journal:  J Exp Med       Date:  1966-03-01       Impact factor: 14.307

View more
  11 in total

1.  Deletion of the Mycobacterium tuberculosis resuscitation-promoting factor Rv1009 gene results in delayed reactivation from chronic tuberculosis.

Authors:  JoAnn M Tufariello; Kaixia Mi; Jiayong Xu; Yukari C Manabe; Anup K Kesavan; Joshua Drumm; Kathryn Tanaka; William R Jacobs; John Chan
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 2.  Animal Models for Tuberculosis in Translational and Precision Medicine.

Authors:  Lingjun Zhan; Jun Tang; Mengmeng Sun; Chuan Qin
Journal:  Front Microbiol       Date:  2017-05-04       Impact factor: 5.640

3.  Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.

Authors:  Mary A De Groote; Janet C Gilliland; Colby L Wells; Elizabeth J Brooks; Lisa K Woolhiser; Veronica Gruppo; Charles A Peloquin; Ian M Orme; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

4.  Redundant and pathogenic roles for IL-22 in mycobacterial, protozoan, and helminth infections.

Authors:  Mark S Wilson; Carl G Feng; Daniel L Barber; Felix Yarovinsky; Allen W Cheever; Alan Sher; Michael Grigg; Mary Collins; Lynette Fouser; Thomas A Wynn
Journal:  J Immunol       Date:  2010-03-10       Impact factor: 5.422

Review 5.  Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis.

Authors:  C Sander; H McShane
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

Review 6.  The emerging role of gasotransmitters in the pathogenesis of tuberculosis.

Authors:  Krishna C Chinta; Vikram Saini; Joel N Glasgow; James H Mazorodze; Md Aejazur Rahman; Darshan Reddy; Jack R Lancaster; Adrie J C Steyn
Journal:  Nitric Oxide       Date:  2016-07-04       Impact factor: 4.427

7.  Airway delivery of silica increases susceptibility to mycobacterial infection in mice: potential role of repopulating macrophages.

Authors:  Rajamouli Pasula; Bradley E Britigan; Joanne Turner; William J Martin
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

8.  The role of resuscitation promoting factors in pathogenesis and reactivation of Mycobacterium tuberculosis during intra-peritoneal infection in mice.

Authors:  Sergey Biketov; Vasilii Potapov; Elena Ganina; Katrina Downing; Bavesh D Kana; Arseny Kaprelyants
Journal:  BMC Infect Dis       Date:  2007-12-17       Impact factor: 3.090

9.  Naturally produced opsonizing antibodies restrict the survival of Mycobacterium tuberculosis in human macrophages by augmenting phagosome maturation.

Authors:  Shashi Kant Kumar; Padam Singh; Sudhir Sinha
Journal:  Open Biol       Date:  2015-12       Impact factor: 6.411

Review 10.  Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis.

Authors:  Nelita du Plessis; Leigh A Kotze; Vinzeigh Leukes; Gerhard Walzl
Journal:  Front Cell Infect Microbiol       Date:  2018-09-21       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.